ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RSV/hMPV/PIV3 formulation 2 at low dose

Also written as “RSV/hMPV/PIV3 formulation 1 at high dose”, “RSV/hMPV/PIV3 formulation 2 at high dose” and “RSV/hMPV/PIV3 formulation 1 at low dose”.

Its studies are mostly in Influenza, Human, led by Sanofi.

Furthest: phase 1, since Feb 11, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi10 open or runningphase 1since Feb 11, 2025Feb 11, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2025First study: phase 1 study in Influenza, HumanFirst studyNCT06850051 · 270 enrolled · Australia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06850051Influenza, Human · Australia1CompletedDec 11, 2025270

How it is read

Names in the registry

  • “RSV/hMPV/PIV3 formulation 2 at low dose”, 1 entry
  • “RSV/hMPV/PIV3 formulation 1 at high dose”, 1 entry
  • “RSV/hMPV/PIV3 formulation 2 at high dose”, 1 entry
  • “RSV/hMPV/PIV3 formulation 1 at low dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.